Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab and Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy

NCT07058012 is registered in ClinicalTrials.gov with NSABP Foundation Inc as lead sponsor.

NCT NCT07058012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07058012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab and Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy
Lead sponsor
NSABP Foundation Inc
Phase
Phase 2
Overall status
Recruiting
Start date
April 17, 2026
Completion date
June 1, 2029
Enrollment
79 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

colo-rectal cancer